New Drug for Blood Cancers Now in Five Phase II Clinical Trials

Researchers at University of California, San Diego School of Medicine have established the safety and dosing of a new drug for treating blood cancers. The findings are published online July 27 in The Lancet Haematology. The drug is a small molecule inhibitor that suppresses the activity of a signaling pathway believed to contribute to a variety of blood cancers' eventual resistance to standard chemotherapy treatments. UC San Diego Moores Cancer Center is one of the 26 NCCN Member Instituti...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news